ABSTRACT
Heart failure (HF) is a leading cause of cardiovascular morbidity and mortality, yet the contribution of common genetic variation to HF risk has not been fully elucidated, particularly in comparison to other common cardiometabolic traits. We conducted a multi-ancestry genome-wide association study (GWAS) meta-analysis of all-cause HF including up to 56,722 HF cases and 1,133,054 controls, identifying 4 novel loci. We then performed a multi-ancestry multivariate association study of HF and related cardiac imaging endophenotypes, identifying 71 conditionally-independent variants, including 16 novel loci. Secondary colocalization and transcriptome-wide association analyses identified known and novel candidate cardiomyopathy genes, which were validated in gene-expression profiling of failing and healthy human hearts. Colocalization, gene expression profiling, and Mendelian randomization provided convergent evidence for the roles of BCKDHA and circulating branch-chain amino acids in heart failure and cardiac structure. Finally, proteome-wide Mendelian randomization revealed 11 circulating proteins associated with HF or quantitative imaging traits. These analyses highlight similarities and differences among heart failure and associated cardiovascular imaging endophenotypes, implicate novel common genetic variation in the pathogenesis of HF, and identify circulating proteins that may represent novel cardiomyopathy treatment targets.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
MGL was supported by the Institute for Translational Medicine and Therapeutics of the Perelman School of Medicine at the University of Pennsylvania and the NIH/NHLBI National Research Service Award postdoctoral fellowship (T32HL007843). BFV is supported by the NIH/NIDDK (DK126194 and DK101478). SMD was supported by US Department of Veterans Affairs grant IK2-CX001780. This publication does not represent the views of the Department of Veterans Affairs or the US government.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The UK Biobank obtained IRB approval from the North West Multi-centre Research Ethics Committee (approval number: 11/NW/0382), and participants provided informed consent. The BioBank Japan Project was approved by the research ethics committees at the Institute of Medical Science, the University of Tokyo, the RIKEN Yokohama Institute, and cooperating hospitals; participants gave written informed consent. FinnGen participants provided informed consent for biobank research, and the Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa (HUS) approved the FinnGen Study protocol No. HUS/990/2017.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Drs. Voight and Damrauer jointly supervised this work
Data Availability
GWAS summary statistics for heart failure (HERMES: http://kp4cd.org/datasets/mi; BioBank Japan: http://jenger.riken.jp/en/result; FinnGen: http://r4.finngen.fi/pheno/I9_HEARTFAIL_ALLCAUSE), cardiac MRI (http://kp4cd.org/datasets/mi, and echocardiography traits (http://jenger.riken.jp/en/result) are publicly available. Cardiac eQTL and RNA expression/sequencing data were provided by the Myocardial Applied Genomics Network (MAGNet).
